Thylacine Bio

Thylacine Biotherapeutics is developing a rapid-response, broad-spectrum antiviral platform. Our novel lipopeptides are designed to target the viruses most likely to cause pandemics, limiting transmission, preventing infection, and reducing disease. Thylacine Bio's lead candidate, THY-01, has demonstrated robust in vivo efficacy and broad-spectrum protection against COVID-19 and other coronaviruses that cause human disease.